Format
Sort by
Items per page

Send to

Choose Destination

Best matches for central serous retinopathy OR retinopathy, central serous:

Central serous chorioretinopathy associated with topical corticosteroids in a patient with psoriasis. Ezra N et al. J Drugs Dermatol. (2011)

Oral rifampin for central serous retinopathy: a strategic approach in three patients. Pouw AE et al. Ophthalmic Surg Lasers Imaging Retina. (2015)

Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Steinle NC et al. Br J Ophthalmol. (2012)

Search results

Items: 1 to 20 of 2011

1.

Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy.

Mohabati D, van Rijssen TJ, van Dijk EH, Luyten GP, Missotten TO, Hoyng CB, Yzer S, Boon CJ.

Clin Ophthalmol. 2018 Jun 7;12:1061-1070. doi: 10.2147/OPTH.S160956. eCollection 2018.

2.

Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy.

Ozdemir I, Eren A, Ersöz G.

Int Ophthalmol. 2018 Jun 18. doi: 10.1007/s10792-018-0950-y. [Epub ahead of print]

PMID:
29916122
3.

Findings of OCT-angiography compared to fluorescein and indocyanine green angiography in central serous chorioretinopathy.

Min JY, Lv Y, Yu S, Gong YY.

Lasers Surg Med. 2018 Jun 12. doi: 10.1002/lsm.22952. [Epub ahead of print]

PMID:
29896889
4.

Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy.

Müller B, Tatsios J, Klonner J, Pilger D, Joussen AM.

Graefes Arch Clin Exp Ophthalmol. 2018 Jun 6. doi: 10.1007/s00417-018-4031-8. [Epub ahead of print]

PMID:
29876733
5.
6.

CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy.

Hosoda Y, Yoshikawa M, Miyake M, Tabara Y, Ahn J, Woo SJ, Honda S, Sakurada Y, Shiragami C, Nakanishi H, Oishi A, Ooto S, Miki A; Nagahama Study Group, Iida T, Iijima H, Nakamura M, Khor CC, Wong TY, Song K, Park KH, Yamada R, Matsuda F, Tsujikawa A, Yamashiro K.

Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6261-6266. doi: 10.1073/pnas.1802212115. Epub 2018 May 29.

7.

Eplerenone as a novel treatment for persistent subretinal fluid following retinal detachment surgery.

Haghighi A, Do J, Ameri H.

Am J Ophthalmol Case Rep. 2018 Mar 9;10:261-263. doi: 10.1016/j.ajoc.2018.03.012. eCollection 2018 Jun.

8.

Central Serous Chorioretinopathy in African Americans at Wilmer Eye Institute.

Mehta PH, Chhablani J, Wang J, Meyerle CB.

J Natl Med Assoc. 2018 Jun;110(3):297-302. doi: 10.1016/j.jnma.2017.06.012. Epub 2017 Jul 27.

PMID:
29778134
9.

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF.

Ophthalmology. 2018 May 15. pii: S0161-6420(17)33463-2. doi: 10.1016/j.ophtha.2018.04.021. [Epub ahead of print]

PMID:
29776672
10.

[Erratum to: Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy. Situation January 2018].

Berufsverband der Augenärzte Deutschlands e. V. (BVA); Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft (RG) e. V.

Ophthalmologe. 2018 May 8. doi: 10.1007/s00347-018-0731-z. [Epub ahead of print] German. No abstract available.

PMID:
29740697
11.

Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results.

Tekin K, Cakar Ozdal P, Gulpamuk B, Yasin Teke M.

Arch Soc Esp Oftalmol. 2018 May 4. pii: S0365-6691(18)30110-2. doi: 10.1016/j.oftal.2018.02.010. [Epub ahead of print] English, Spanish.

PMID:
29735320
12.

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.

van Rijssen TJ, van Dijk EHC, Dijkman G, Boon CJF.

Graefes Arch Clin Exp Ophthalmol. 2018 May 7. doi: 10.1007/s00417-018-4003-z. [Epub ahead of print]

PMID:
29732468
13.

Macular Integrity Assessment and Fixation Analysis in Chronic Central Serous Chorioretinopathy.

Dolar-Szczasny J, Święch-Zubilewicz A, Mackiewicz J.

J Ophthalmol. 2018 Mar 14;2018:9479848. doi: 10.1155/2018/9479848. eCollection 2018.

14.

Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline.

Nikkhah H, Karimi S, Ahmadieh H, Azarmina M, Abrishami M, Ahoor H, Alizadeh Y, Behboudi H, Daftarian N, Dehghan MH, Entezari M, Farrahi F, Ghanbari H, Falavarjani KG, Javadi MA, Karkhaneh R, Moradian S, Manaviat MR, Mehryar M, Nourinia R, Parvaresh MM, Ramezani A, Haghi AR, Riazi-Esfahani M, Soheilian M, Shahsavari M, Shahriari HA, Rajavi Z, Safi S, Shirvani A, Rahmani S, Sabbaghi H, Pakbin M, Kheiri B, Ziaei H.

J Ophthalmic Vis Res. 2018 Apr-Jun;13(2):158-169. doi: 10.4103/jovr.jovr_50_18.

15.

Leopard-Spot Subretinal Deposits in Central Serous Chorioretinopathy.

Marchese A, Miserocchi E, Modorati G, Querques G, Bandello F.

Retina. 2018 Jul;38(7):e53-e54. doi: 10.1097/IAE.0000000000002204. No abstract available.

PMID:
29697592
16.

Macular telangiectasia type II with pachychoroid spectrum of macular disorders.

Kumar V, Kumar P, Ravani R, Gupta P.

Eur J Ophthalmol. 2018 Apr 1:1120672118769527. doi: 10.1177/1120672118769527. [Epub ahead of print]

PMID:
29676172
17.

Mineralocorticoid receptor inhibitor for long-standing central serous chorioretinopathy.

Suzuki A, Takano Y, Ando Y, Ogawa J, Ishida M, Baba A, Imamura Y.

Acta Ophthalmol. 2018 Apr 19. doi: 10.1111/aos.13780. [Epub ahead of print] No abstract available.

PMID:
29671951
18.

The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels.

Çiloğlu E, Unal F, Dogan NC.

Graefes Arch Clin Exp Ophthalmol. 2018 Jun;256(6):1111-1116. doi: 10.1007/s00417-018-3985-x. Epub 2018 Apr 18.

PMID:
29671064
19.

Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy.

Zola M, Chatziralli I, Menon D, Schwartz R, Hykin P, Sivaprasad S.

Acta Ophthalmol. 2018 Apr 15. doi: 10.1111/aos.13742. [Epub ahead of print]

PMID:
29656602
20.

Central Serous Chorioretinopathy Associated with Desmopressin Nasal Spray: Causality or Unfortunate Association.

Kisma N, Loukianou E, Pal B.

Case Rep Ophthalmol. 2018 Feb 6;9(1):120-125. doi: 10.1159/000485912. eCollection 2018 Jan-Apr.

Supplemental Content

Loading ...
Support Center